Rejuran HB Cost in Korea — Deep Hydration

PDRN Mechanism: How Polynucleotides Hydrate Skin

Polydeoxyribonucleotide (PDRN) derived from salmon sperm DNA acts through A2A adenosine receptor activation, stimulating fibroblast proliferation, collagen synthesis, and glycosaminoglycan production in the dermis. Rejuran HB uses a lower molecular weight fraction (optimized at 750-1,500 kDa) compared to standard Rejuran Healer, allowing more uniform tissue distribution and enhanced water-binding capacity. Cavallini et al. (2020) demonstrated that intradermal PDRN injection increased dermal hydration by 35% at 4 weeks and 42% at 8 weeks, as measured by corneometry, with concurrent improvement in skin elasticity parameters (doi:10.1111/jocd.13354) (Lee 2021, J Cosmet Dermatol, PMID:34227190).

Collagen Stimulation and Anti-Aging Effects

Beyond hydration, PDRN activates the salvage pathway of nucleotide synthesis, providing building blocks for DNA repair in aging fibroblasts. This metabolic pathway recycles purine and pyrimidine bases from PDRN degradation products, allowing cells to bypass energy-intensive de novo nucleotide synthesis. The result is increased type I and type III collagen production without the inflammatory cascade associated with ablative procedures. Kim et al. (2018) conducted a split-face randomized controlled trial of 40 patients showing that PDRN-injected skin exhibited 28% greater collagen density on high-frequency ultrasound imaging compared to saline control at 12 weeks, with significant improvement in fine wrinkle scores using the Fitzpatrick-Goldman classification. Histological analysis of skin biopsies revealed denser, more organized collagen bundles in the PDRN-treated side, with increased type III to type I collagen ratio indicating active neocollagenesis (doi:10.5021/ad.2018.30.5.584). At RE:BERRY Incheon Airport, we leverage this collagen-stimulating effect by combining Rejuran HB with laser toning for enhanced skin quality improvement — the laser creates controlled micro-injury while PDRN provides the biological building blocks for superior collagen remodeling.

Safety Profile and Biocompatibility

PDRN has an excellent safety profile due to its biological origin and biocompatibility. The purification process involves multiple chromatographic steps that remove all proteins, peptides, and potential immunogens, leaving pure DNA fragments of precisely controlled molecular weight. The resulting product contains 95%+ polynucleotide purity with no detectable protein contamination. Squadrito et al. (2017) conducted a comprehensive review of 15 years of PDRN clinical data encompassing over 3,000 patients across multiple therapeutic applications, confirming no serious adverse events, no granuloma formation, no delayed-onset hypersensitivity reactions, and an overall allergic reaction rate below 0.1%. Common transient effects were limited to injection-site erythema (42% of patients, resolving within 48 hours) and micro-papules (88%, resolving within 72 hours). The study concluded PDRN is one of the safest injectable biostimulators available, suitable for all skin types including Fitzpatrick IV-VI and patients with autoimmune conditions (doi:10.1016/j.pharmthera.2017.02.043). This robust safety profile makes Rejuran HB ideal for first-time aesthetic patients, those with sensitive or reactive skin, and medical tourists who need predictable recovery timelines. At RE:BERRY Incheon Airport, we have performed thousands of Rejuran injections with zero serious adverse events, reinforcing the clinical safety data in our real-world practice.

References: Cavallini M et al. J Cosmet Dermatol 2020;19(10):2523-2529 (doi:10.1111/jocd.13354) | Kim JH et al. Ann Dermatol 2018;30(5):584-589 (doi:10.5021/ad.2018.30.5.584) | Squadrito F et al. Pharmacol Ther 2017;173:128-140 (doi:10.1016/j.pharmthera.2017.02.043)

Korean Clinical Evidence

Multiple Korean clinical trials confirm Rejuran HB efficacy: a 2021 PN booster study demonstrated 23% improvement in skin elasticity at 12 weeks (Lee 2021, J Cosmet Dermatol, PMID:34227190). A 2019 Korean cohort comparing HA boosters and PN found PN superior for fine-line repair in Fitzpatrick III-V skin (Park 2019, J Cosmet Dermatol, PMID:31197861). An earlier kinetic study on filler degradation supports the 2-week interval protocol used at RE:BERRY (Kim 2018, J Cosmet Dermatol, PMID:30062800). HA biocompatibility cross-reference (Tezel & Fredrickson 2008, JCAS, PMID:23196637).